Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Capital Expenditures (2022 - 2025)

Historic Capital Expenditures for TriSalus Life Sciences (TLSI) over the last 4 years, with Q3 2025 value amounting to $216000.0.

  • TriSalus Life Sciences' Capital Expenditures rose 2781.07% to $216000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $927000.0, marking a year-over-year increase of 3898.05%. This contributed to the annual value of $345000.0 for FY2024, which is 4132.65% down from last year.
  • As of Q3 2025, TriSalus Life Sciences' Capital Expenditures stood at $216000.0, which was up 2781.07% from -$93000.0 recorded in Q2 2025.
  • In the past 5 years, TriSalus Life Sciences' Capital Expenditures ranged from a high of $754000.0 in Q1 2025 and a low of -$93000.0 during Q2 2025
  • For the 4-year period, TriSalus Life Sciences' Capital Expenditures averaged around $167833.3, with its median value being $117500.0 (2024).
  • Over the last 5 years, TriSalus Life Sciences' Capital Expenditures had its largest YoY gain of 104242.42% in 2025, and its largest YoY loss of 25500.0% in 2025.
  • Quarter analysis of 4 years shows TriSalus Life Sciences' Capital Expenditures stood at $204000.0 in 2022, then soared by 82.35% to $372000.0 in 2023, then tumbled by 86.56% to $50000.0 in 2024, then surged by 332.0% to $216000.0 in 2025.
  • Its last three reported values are $216000.0 in Q3 2025, -$93000.0 for Q2 2025, and $754000.0 during Q1 2025.